Nuveen Asset Management LLC Trims Holdings in Inspire Medical Systems, Inc. (NYSE:INSP)

Nuveen Asset Management LLC trimmed its position in Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) by 15.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 153,468 shares of the company's stock after selling 27,132 shares during the period. Nuveen Asset Management LLC owned approximately 0.51% of Inspire Medical Systems worth $28,450,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Mutual of America Capital Management LLC grew its position in Inspire Medical Systems by 1.2% in the 4th quarter. Mutual of America Capital Management LLC now owns 4,540 shares of the company's stock valued at $842,000 after buying an additional 55 shares during the last quarter. Captrust Financial Advisors grew its position in Inspire Medical Systems by 2.0% in the 4th quarter. Captrust Financial Advisors now owns 3,034 shares of the company's stock valued at $562,000 after buying an additional 59 shares during the last quarter. MML Investors Services LLC grew its position in Inspire Medical Systems by 0.9% in the 4th quarter. MML Investors Services LLC now owns 7,941 shares of the company's stock valued at $1,472,000 after buying an additional 67 shares during the last quarter. Mariner LLC grew its position in Inspire Medical Systems by 1.6% in the 4th quarter. Mariner LLC now owns 4,837 shares of the company's stock valued at $897,000 after buying an additional 77 shares during the last quarter. Finally, Xponance Inc. grew its position in Inspire Medical Systems by 2.2% in the 4th quarter. Xponance Inc. now owns 3,824 shares of the company's stock valued at $709,000 after buying an additional 82 shares during the last quarter. 94.91% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Piper Sandler lowered their price objective on shares of Inspire Medical Systems from $260.00 to $233.00 and set an "overweight" rating on the stock in a research report on Monday, February 10th. Royal Bank of Canada decreased their target price on shares of Inspire Medical Systems from $260.00 to $215.00 and set an "outperform" rating on the stock in a research report on Tuesday, April 15th. Wells Fargo & Company decreased their target price on shares of Inspire Medical Systems from $195.00 to $174.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. JPMorgan Chase & Co. decreased their target price on shares of Inspire Medical Systems from $235.00 to $195.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 6th. Finally, Stifel Nicolaus decreased their target price on shares of Inspire Medical Systems from $190.00 to $175.00 and set a "hold" rating on the stock in a research report on Monday, April 21st. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $211.91.

Inspire Medical Systems Stock Down 0.1%

Shares of Inspire Medical Systems stock traded down $0.13 on Tuesday, hitting $143.08. The company's stock had a trading volume of 514,026 shares, compared to its average volume of 557,900. Inspire Medical Systems, Inc. has a 52-week low of $123.00 and a 52-week high of $225.00. The firm has a fifty day moving average price of $153.13 and a 200-day moving average price of $174.24. The company has a market capitalization of $4.22 billion, a P/E ratio of 82.70, a price-to-earnings-growth ratio of 2.86 and a beta of 1.39.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.23) by $0.33. Inspire Medical Systems had a net margin of 6.67% and a return on equity of 8.19%. The business had revenue of $201.32 million for the quarter, compared to analyst estimates of $194.89 million. During the same period in the previous year, the firm earned ($0.34) EPS. The business's revenue for the quarter was up 22.7% compared to the same quarter last year. As a group, analysts expect that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current year.

Insider Buying and Selling

In other Inspire Medical Systems news, Director Shawn Mccormick sold 360 shares of the company's stock in a transaction dated Friday, May 2nd. The shares were sold at an average price of $160.00, for a total value of $57,600.00. Following the transaction, the director now directly owns 24,046 shares in the company, valued at approximately $3,847,360. This represents a 1.48% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 4.10% of the company's stock.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.